Phreesia, Inc. (NYSE:PHR) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP lessened its stake in shares of Phreesia, Inc. (NYSE:PHR) by 9.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 150,958 shares of the company’s stock after selling 14,862 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.26% of Phreesia worth $3,799,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in PHR. Charles Schwab Investment Management Inc. grew its holdings in Phreesia by 10.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 493,448 shares of the company’s stock valued at $12,415,000 after buying an additional 46,209 shares during the period. Wesbanco Bank Inc. raised its position in shares of Phreesia by 76.9% in the 4th quarter. Wesbanco Bank Inc. now owns 46,000 shares of the company’s stock valued at $1,157,000 after purchasing an additional 20,000 shares in the last quarter. Barclays PLC raised its position in shares of Phreesia by 83.6% in the 3rd quarter. Barclays PLC now owns 94,929 shares of the company’s stock valued at $2,163,000 after purchasing an additional 43,225 shares in the last quarter. Proficio Capital Partners LLC acquired a new position in shares of Phreesia in the 4th quarter valued at approximately $377,000. Finally, M&T Bank Corp increased its holdings in shares of Phreesia by 56.4% in the 4th quarter. M&T Bank Corp now owns 54,939 shares of the company’s stock valued at $1,382,000 after acquiring an additional 19,812 shares during the last quarter. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Insider Activity at Phreesia

In other Phreesia news, General Counsel Allison C. Hoffman sold 3,496 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $29.72, for a total transaction of $103,901.12. Following the completion of the sale, the general counsel now directly owns 142,630 shares of the company’s stock, valued at approximately $4,238,963.60. The trade was a 2.39% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP David Linetsky sold 4,499 shares of the company’s stock in a transaction dated Wednesday, April 16th. The shares were sold at an average price of $23.73, for a total value of $106,761.27. Following the completion of the sale, the senior vice president now directly owns 217,239 shares of the company’s stock, valued at approximately $5,155,081.47. This trade represents a 2.03% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 111,640 shares of company stock valued at $3,094,167 in the last 90 days. 5.80% of the stock is owned by corporate insiders.

Phreesia Price Performance

Shares of PHR stock opened at $26.10 on Wednesday. The stock’s fifty day simple moving average is $25.12 and its 200 day simple moving average is $24.83. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74. The firm has a market cap of $1.53 billion, a price-to-earnings ratio of -17.75 and a beta of 0.74. Phreesia, Inc. has a one year low of $17.07 and a one year high of $30.53.

Analysts Set New Price Targets

Several research analysts have recently issued reports on PHR shares. KeyCorp decreased their price target on Phreesia from $30.00 to $28.00 and set an “overweight” rating for the company in a research note on Wednesday, April 16th. DA Davidson reduced their price objective on Phreesia from $36.00 to $34.00 and set a “buy” rating for the company in a research note on Monday, April 14th. Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 price target on shares of Phreesia in a research note on Thursday, March 13th. Piper Sandler reissued an “overweight” rating and set a $33.00 price objective (up previously from $31.00) on shares of Phreesia in a report on Wednesday, January 29th. Finally, Canaccord Genuity Group lifted their price target on Phreesia from $34.00 to $35.00 and gave the stock a “buy” rating in a research report on Thursday, March 13th. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Phreesia presently has a consensus rating of “Buy” and a consensus price target of $31.33.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.